ALLO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 27.40%

Insider Buying (Last 12 Months): $684.00

Insider Selling (Last 12 Months): $93,228.00

Allogene Therapeutics Insider Trading History Chart

Allogene Therapeutics Share Price & Price History

^$2.86

▼ -0.19 (-6.24%)

As of 04/25/2024 01:00 AM ET

Days: 30 | 90 | 365

Thousands of investors use this no cost solution | Do you?

From Insider Financial | Ad

In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.

Simply tap here now to subscribe and start getting "Insider Financial Advantage"

Allogene Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/30/2024	Geoffrey M Parker	CFO	Buy	190	$3.60	$684.00	819,590
12/18/2023	Deborah M Messemer	Director	Sell	18,640	$2.70	$50,328.00	62,456
8/7/2023	Stephen Mayo	Director	Sell	10,000	$4.29	$42,900.00	25,328
2/13/2023	Veer Bhavnagri	General Counsel	Sell	3,000	$6.85	$20,550.00	577,677
1/17/2023	Veer Bhavnagri	General Counsel	Sell	3,000	$7.04	$21,120.00	580,677
12/15/2022	Veer Bhavnagri	General Counsel	Sell	5,602	$7.53	$42,183.06	583,677
8/11/2022	Owen N. Witte	Director	Sell	10,000	$16.50	$165,000.00	223,271
8/2/2022	Rafael Amado	CMO	Sell	2,000	$11.97	$23,940.00	540,257
7/5/2022	Rafael Amado	CMO	Sell	2,000	$11.44	$22,880.00	542,257
6/22/2022	Owen N. Witte	Director	Sell	10,000	$11.76	$117,600.00	233,271
6/21/2022	Rafael Amado	CMO	Sell	2,000	$11.18	$22,360.00	544,257
5/19/2022	Rafael Amado	CMO	Sell	11,500	$7.40	$85,100.00	546,257
3/15/2022	Alison Moore	Insider	Sell	8,698	$7.63	$66,365.74
3/15/2022	David D Chang	CEO	Sell	23,648	$7.65	$180,907.20
3/15/2022	Eric Thomas Schmidt	CFO	Sell	11,469	$7.63	$87,508.47
3/15/2022	Rafael Amado	CMO	Sell	5,169	$7.71	$39,852.99
3/15/2022	Veer Bhavnagri	General Counsel	Sell	8,849	$7.68	$67,960.32
1/12/2022	Arie Belldegrun	Director	Buy	155,039	$12.60	$1,953,491.40
10/1/2021	Rafael Amado	CMO	Sell	11,507	$24.35	$280,195.45
9/9/2021	Owen N. Witte	Director	Sell	5,000	$25.54	$127,700.00	221,182
8/20/2021	Owen N. Witte	Director	Sell	10,000	$23.47	$234,700.00
8/16/2021	Veer Bhavnagri	General Counsel	Sell	5,000	$21.00	$105,000.00
7/15/2021	Veer Bhavnagri	General Counsel	Sell	5,000	$21.55	$107,750.00	426,353
6/9/2021	Owen N. Witte	Director	Sell	9,969	$25.05	$249,723.45	236,182
5/18/2021	Veer Bhavnagri	General Counsel	Sell	5,000	$30.00	$150,000.00	426,353

Thousands of investors use this no cost solution | Do you?

From Insider Financial | Ad

Simply tap here now to subscribe and start getting "Insider Financial Advantage"

SEC Filings (Institutional Ownership Changes) for Allogene Therapeutics (NASDAQ:ALLO)

83.63% of Allogene Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Allogene Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/19/2024	Bourgeon Capital Management LLC	57,200	$0.26M	0.1%	+12.8%	0.034%
4/5/2024	Los Angeles Capital Management LLC	160,623	$0.72M	0.0%	-3.2%	0.095%
2/14/2024	Caxton Associates LP	775,093	$2.49M	0.1%	+61.4%	0.461%
2/14/2024	Pennant Investors LP	128,400	$0.41M	0.1%	N/A	0.076%
2/14/2024	Superstring Capital Management LP	222,112	$0.71M	0.5%	N/A	0.132%
2/13/2024	Affinity Asset Advisors LLC	400,000	$1.28M	0.2%	N/A	0.238%
2/12/2024	RPO LLC	14,333	$46K	0.1%	N/A	0.009%
2/9/2024	Primecap Management Co. CA	5,281,886	$16.96M	0.0%	0.0%	3.139%
2/8/2024	Mitsubishi UFJ Asset Management Co. Ltd.	221,094	$0.74M	0.0%	+20.2%	0.131%
2/7/2024	BNP Paribas Financial Markets	123,518	$0.40M	0.0%	-78.3%	0.073%
2/7/2024	Calton & Associates Inc.	21,060	$68K	0.0%	N/A	0.013%
2/6/2024	Axxcess Wealth Management LLC	10,677	$34K	0.0%	N/A	0.006%
2/6/2024	Los Angeles Capital Management LLC	165,978	$0.53M	0.0%	N/A	0.099%
2/6/2024	Swiss National Bank	214,800	$0.69M	0.0%	+11.6%	0.128%
2/5/2024	Victory Capital Management Inc.	14,283	$46K	0.0%	+23.1%	0.008%
1/31/2024	Daiwa Securities Group Inc.	32,498	$0.10M	0.0%	+116.3%	0.019%
1/30/2024	Zurcher Kantonalbank Zurich Cantonalbank	22,551	$72K	0.0%	+55.4%	0.013%
1/30/2024	Bourgeon Capital Management LLC	50,700	$0.16M	0.0%	-17.8%	0.030%
1/30/2024	Cornercap Investment Counsel Inc.	60,634	$0.20M	0.0%	N/A	0.036%
1/30/2024	Vontobel Holding Ltd.	18,000	$58K	0.0%	+28.6%	0.011%
1/26/2024	Cerity Partners LLC	517,581	$1.66M	0.0%	N/A	0.308%
1/26/2024	Aaron Wealth Advisors LLC	10,729	$34K	0.0%	N/A	0.006%
1/24/2024	Mirae Asset Global Investments Co. Ltd.	195,480	$0.63M	0.0%	-54.4%	0.116%
1/24/2024	Arizona State Retirement System	30,458	$98K	0.0%	+22.2%	0.018%
1/24/2024	China Universal Asset Management Co. Ltd.	19,467	$62K	0.0%	+353.0%	0.012%
1/18/2024	McGlone Suttner Wealth Management Inc.	8,376	$27K	0.0%	N/A	0.005%
1/12/2024	SG Americas Securities LLC	53,484	$0.17M	0.0%	N/A	0.032%
1/10/2024	Nordea Investment Management AB	740,683	$2.38M	0.0%	-3.1%	0.440%
1/8/2024	Harbor Capital Advisors Inc.	73,510	$0.24M	0.0%	+7.3%	0.044%
1/5/2024	Exchange Traded Concepts LLC	36,040	$0.12M	0.0%	+34.0%	0.021%
12/18/2023	Vanguard Group Inc.	10,587,804	$33.56M	0.0%	+41.1%	6.292%
11/24/2023	EP Wealth Advisors LLC	10,850	$34K	0.0%	N/A	0.006%
11/15/2023	Alps Advisors Inc.	123,718	$0.39M	0.0%	+15.4%	0.074%
11/14/2023	Corton Capital Inc.	12,628	$40K	0.0%	-52.5%	0.008%
11/14/2023	Caxton Associates LP	480,104	$1.52M	0.2%	+590.0%	0.285%
11/14/2023	MBB Public Markets I LLC	57,306	$0.18M	0.0%	-33.2%	0.034%
11/14/2023	Primecap Management Co. CA	5,284,386	$16.75M	0.0%	-6.3%	3.140%
11/14/2023	Profund Advisors LLC	130,639	$0.41M	0.0%	-4.8%	0.078%
11/13/2023	FMR LLC	25,143,931	$79.71M	0.0%	+0.9%	14.942%
11/13/2023	Nordea Investment Management AB	764,488	$2.42M	0.0%	-1.4%	0.454%
11/13/2023	Rafferty Asset Management LLC	904,403	$2.87M	0.0%	+2.2%	0.537%
11/9/2023	Citigroup Inc.	338,756	$1.07M	0.0%	+20.4%	0.201%
11/8/2023	Dorsey & Whitney Trust CO LLC	12,265	$39K	0.0%	N/A	0.007%
11/8/2023	Swiss National Bank	192,400	$0.61M	0.0%	+3.0%	0.115%
11/7/2023	Barclays PLC	786,793	$2.50M	0.0%	+17.6%	0.469%
11/6/2023	Victory Capital Management Inc.	11,603	$37K	0.0%	N/A	0.007%
11/6/2023	Ieq Capital LLC	66,178	$0.21M	0.0%	+45.4%	0.039%
11/2/2023	Principal Financial Group Inc.	266,154	$0.84M	0.0%	+1.7%	0.159%
11/1/2023	Bourgeon Capital Management LLC	61,700	$0.20M	0.0%	-7.8%	0.037%
10/27/2023	TD Asset Management Inc	237,836	$0.75M	0.0%	+19.2%	0.142%
10/26/2023	Mirae Asset Global Investments Co. Ltd.	428,493	$1.36M	0.0%	+8.3%	0.256%
10/20/2023	Harbor Capital Advisors Inc.	68,519	$0.22M	0.0%	+18.0%	0.041%
9/21/2023	Barclays PLC	669,197	$3.33M	0.0%	+33.7%	0.399%
8/14/2023	Partners Capital Investment Group LLP	454,845	$2.26M	0.0%	+387.8%	0.271%
8/14/2023	Graham Capital Management L.P.	62,431	$0.31M	0.0%	+198.6%	0.037%
8/11/2023	Campbell & CO Investment Adviser LLC	18,952	$94K	0.0%	N/A	0.011%
8/11/2023	Inceptionr LLC	16,203	$81K	0.0%	N/A	0.010%
8/11/2023	Schroder Investment Management Group	168,864	$0.84M	0.0%	-5.1%	0.101%
8/11/2023	E Fund Management Co. Ltd.	41,061	$0.20M	0.0%	+6.8%	0.024%
8/11/2023	JPMorgan Chase & Co.	6,134,395	$30.49M	0.0%	+22.1%	3.659%
8/11/2023	Penserra Capital Management LLC	21,175	$0.11M	0.0%	+16.9%	0.013%
8/11/2023	ExodusPoint Capital Management LP	427,752	$2.13M	0.0%	-36.7%	0.255%
8/10/2023	Profund Advisors LLC	137,232	$0.68M	0.0%	+10.1%	0.082%
8/10/2023	Crosspoint Financial LLC	12,000	$60K	0.6%	N/A	0.007%
8/10/2023	Mirae Asset Global Investments Co. Ltd.	395,723	$1.96M	0.0%	+8.4%	0.236%
8/10/2023	Citigroup Inc.	281,364	$1.40M	0.0%	-49.3%	0.168%
8/9/2023	BNP Paribas Arbitrage SNC	237,295	$1.18M	0.0%	-10.3%	0.142%
8/9/2023	TD Asset Management Inc	199,479	$0.99M	0.0%	+14.9%	0.119%
8/9/2023	Mitsubishi UFJ Kokusai Asset Management Co. Ltd.	183,963	$0.91M	0.0%	+11.2%	0.110%
8/8/2023	Ieq Capital LLC	45,530	$0.23M	0.0%	+5.9%	0.027%
8/3/2023	Los Angeles Capital Management LLC	41,227	$0.21M	0.0%	N/A	0.028%
8/3/2023	Barclays PLC	669,197	$3.33M	0.0%	+33.7%	0.459%
8/3/2023	Mackenzie Financial Corp	53,192	$0.26M	0.0%	N/A	0.036%
8/3/2023	Oppenheimer & Co. Inc.	12,400	$62K	0.0%	N/A	0.009%
7/31/2023	Orin Green Financial LLC	15,990	$79K	0.0%	N/A	0.011%
7/31/2023	Daiwa Securities Group Inc.	15,027	$75K	0.0%	+2,708.8%	0.010%
7/24/2023	Vontobel Holding Ltd.	14,000	$70K	0.0%	-41.7%	0.010%
7/20/2023	Bourgeon Capital Management LLC	66,950	$0.33M	0.1%	+139.5%	0.046%
7/20/2023	Shikiar Asset Management Inc.	15,750	$78K	0.0%	-32.3%	0.011%
7/20/2023	Exchange Traded Concepts LLC	24,937	$0.12M	0.0%	N/A	0.017%
7/19/2023	Teacher Retirement System of Texas	23,521	$0.12M	0.0%	-11.8%	0.016%
7/11/2023	Harbor Capital Advisors Inc.	58,046	$0.29M	0.1%	+10.0%	0.040%
7/7/2023	Nordea Investment Management AB	775,295	$3.73M	0.0%	+20.1%	0.532%
5/23/2023	Capital Impact Advisors LLC	26,076	$0.13M	0.2%	+54.3%	0.018%
5/16/2023	Baker BROS. Advisors LP	1,576,901	$7.79M	0.0%	N/A	1.081%
5/12/2023	Profund Advisors LLC	124,611	$0.62M	0.0%	N/A	0.085%
5/12/2023	Rhenman & Partners Asset Management AB	300,000	$1.49M	0.2%	-11.8%	0.206%
5/11/2023	RMB Capital Management LLC	38,835	$0.19M	0.0%	+34.0%	0.027%
5/11/2023	Cerity Partners LLC	600,054	$2.96M	0.0%	+1.8%	0.411%
5/11/2023	ExodusPoint Capital Management LP	675,279	$3.34M	0.0%	-41.7%	0.463%
5/11/2023	Citigroup Inc.	555,343	$2.74M	0.0%	+61.3%	0.381%
5/10/2023	Simplify Asset Management Inc.	245,000	$1.21M	0.2%	N/A	0.168%
5/9/2023	Integral Health Asset Management LLC	405,000	$2M	0.4%	N/A	0.278%
5/8/2023	Mitsubishi UFJ Kokusai Asset Management Co. Ltd.	165,378	$0.82M	0.0%	+1.2%	0.113%
5/4/2023	Barclays PLC	500,651	$2.47M	0.0%	+18.3%	0.343%
5/4/2023	Mirae Asset Global Investments Co. Ltd.	364,974	$1.80M	0.0%	+8.4%	0.250%
5/3/2023	Jump Financial LLC	219,762	$1.09M	0.0%	+102.5%	0.151%
5/3/2023	Beck Bode LLC	94,716	$0.47M	0.1%	N/A	0.065%
5/2/2023	Amalgamated Bank	8,246	$41K	0.0%	-19.1%	0.006%
5/2/2023	Ieq Capital LLC	43,000	$0.21M	0.0%	+95.5%	0.029%

Data available starting January 2016

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Today's Range

Now: $2.86

$2.84

$2.99

50 Day Range

MA: $4.40

$3.04

$5.63

52 Week Range

Now: $2.86

$2.23

$6.89

Volume

2,772,425 shs

Average Volume

2,551,846 shs

Market Capitalization

$482.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

Who are the company insiders with the largest holdings of Allogene Therapeutics?: Allogene Therapeutics' top insider shareholders include:
Geoffrey M Parker (CFO)
Veer Bhavnagri (General Counsel)
Rafael Amado (CMO)
Owen N Witte (Director)
Deborah M Messemer (Director)
Stephen Mayo (Director)
Learn More about top insider investors at Allogene Therapeutics.
Who are the major institutional investors of Allogene Therapeutics?: Allogene Therapeutics' top institutional shareholders include:
Los Angeles Capital Management LLC — 0.09%
Bourgeon Capital Management LLC — 0.03%
Simplex Trading LLC — 0.00%
Learn More about top institutional investors of Allogene Therapeutics stock.
Which institutional investors are selling Allogene Therapeutics stock?: During the previous quarter, ALLO stock was sold by these institutional investors:
Los Angeles Capital Management LLC
Within the previous year, company insiders that have sold Allogene Therapeutics company stock include:
Geoffrey M Parker (CFO)
Veer Bhavnagri (General Counsel)
Learn More investors selling Allogene Therapeutics stock.
Which institutional investors are buying Allogene Therapeutics stock?: During the previous quarter, ALLO stock was acquired by institutional investors including:
Bourgeon Capital Management LLC
Simplex Trading LLC